Evercore Downgrades Intellia (NTLA) Despite Strong ATTR Trial Data

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, Evercore ISI downgraded Intellia Therapeutics (NASDAQ:NTLA) from Outperform to In Line and cut its price target to $8 from $17, citing uncertainty around the company’s ATTR program timeline. While acknowledging promising efficacy updates, the firm noted that clarity on development milestones remains lacking, narrowing the path to value. Evercore Downgrades Intellia (NTLA) Despi ...